These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 22262590)

  • 1. Design considerations, architecture, and use of the Mini-Sentinel distributed data system.
    Curtis LH; Weiner MG; Boudreau DM; Cooper WO; Daniel GW; Nair VP; Raebel MA; Beaulieu NU; Rosofsky R; Woodworth TS; Brown JS
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():23-31. PubMed ID: 22262590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
    Platt R; Carnahan RM; Brown JS; Chrischilles E; Curtis LH; Hennessy S; Nelson JC; Racoosin JA; Robb M; Schneeweiss S; Toh S; Weiner MG
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():1-8. PubMed ID: 22262586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 4. A policy framework for public health uses of electronic health data.
    McGraw D; Rosati K; Evans B
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():18-22. PubMed ID: 22262589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program.
    Forrow S; Campion DM; Herrinton LJ; Nair VP; Robb MA; Wilson M; Platt R
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():12-7. PubMed ID: 22262588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise.
    Nguyen M; Ball R; Midthun K; Lieu TA
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():291-7. PubMed ID: 22262619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned.
    Carnahan RM; Moores KG
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():82-9. PubMed ID: 22262596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system.
    Rassen JA; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():41-9. PubMed ID: 22262592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.
    Cook AJ; Tiwari RC; Wellman RD; Heckbert SR; Li L; Heagerty P; Marsh T; Nelson JC
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():72-81. PubMed ID: 22262595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active surveillance of postmarket medical product safety in the Federal Partners' Collaboration.
    Robb MA; Racoosin JA; Worrall C; Chapman S; Coster T; Cunningham FE
    Med Care; 2012 Nov; 50(11):948-53. PubMed ID: 23047784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study.
    Velentgas P; Bohn RL; Brown JS; Chan KA; Gladowski P; Holick CN; Kramer JM; Nakasato C; Spettell CM; Walker AM; Zhang F; Platt R
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1226-34. PubMed ID: 18956428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design considerations in an active medical product safety monitoring system.
    Gagne JJ; Fireman B; Ryan PB; Maclure M; Gerhard T; Toh S; Rassen JA; Nelson JC; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():32-40. PubMed ID: 22262591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.
    Fireman B; Toh S; Butler MG; Go AS; Joffe HV; Graham DJ; Nelson JC; Daniel GW; Selby JV
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():282-90. PubMed ID: 22262618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.
    Xu Y; Zhou X; Suehs BT; Hartzema AG; Kahn MG; Moride Y; Sauer BC; Liu Q; Moll K; Pasquale MK; Nair VP; Bate A
    Drug Saf; 2015 Aug; 38(8):749-65. PubMed ID: 26055920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
    Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
    Maro JC; Brown JS
    Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs.
    Toh S; Avorn J; D'Agostino RB; Gurwitz JH; Psaty BM; Rothman KJ; Saag KG; Sturkenboom MC; Vandenbroucke JP; Winterstein AG; Strom BL
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1036-45. PubMed ID: 23922322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a database computer program to identify trends in reporting of adverse drug reactions.
    Johnston PE; Morrow JD; Branch RA
    Am J Hosp Pharm; 1990 Jun; 47(6):1321-7. PubMed ID: 2368725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership.
    Stang PE; Ryan PB; Racoosin JA; Overhage JM; Hartzema AG; Reich C; Welebob E; Scarnecchia T; Woodcock J
    Ann Intern Med; 2010 Nov; 153(9):600-6. PubMed ID: 21041580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical device vigilance at FDA.
    Gross TP; Kessler LG
    Stud Health Technol Inform; 1996; 28():17-24. PubMed ID: 10164091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.